Breast Cancer Research

Breast cancer research focuses on early detection, targeted therapies, immunotherapy, and personalized treatment approaches.

Our Breast Cancer Analysis

• July 24, 2026Annals of OncologyNCT01272037

  Low Ovarian Reserve Predicts No Chemotherapy Benefit in Node-Positive, HR-Positive Breast Cancer

  A prespecified biomarker analysis of the phase 3 RxPONDER (SWOG S1007) trial finds that serum anti-Müllerian hormone (AMH), a marker of ovarian reserve, identifies which women under 55 with hormone receptor-positive, HER2-negative, node-positive breast cancer actually benefit from adding chemotherapy to endocrine therapy — outperforming menopausal status and age as a predictor.

• May 28, 2026Annals of OncologyNCT02308085

  Pregnancy After Interrupting Endocrine Therapy Shows No Excess Breast Cancer Risk at 6 Years

  Updated results from the prospective, single-arm POSITIVE trial — now with a median follow-up of 71 months, up from 41 months at the original analysis — found no increase in breast cancer recurrence risk among young women with hormone receptor-positive disease who paused adjuvant endocrine therapy to attempt pregnancy.

• August 20, 2026JAMA Oncology

  Industry Now Outpaces Federal Cancer Trial Sponsorship Nearly 5 to 1 — And the Gap Is Widening

  A registry-based analysis of 11,681 US interventional cancer trials registered on ClinicalTrials.gov between 2008 and 2024 found that industry sponsors now outnumber federal sponsors nearly 5 to 1 (4.53-to-1 overall), with the ratio widening from 2.72-to-1 in 2008–2012 to 6.44-to-1 in 2019–2024.

• August 13, 2026JAMA Oncologyc-TRAK TN (NCT03145961)

  Tissue-Free ctDNA Testing Matches Tumor-Informed Assays for Detecting TNBC Recurrence

  In a prognostic analysis nested within the phase 2 c-TRAK TN trial, a tissue-free ctDNA assay detected molecular residual disease in 54 of 159 patients (34.0%) with early triple negative breast cancer, and detection was strongly associated with recurrence risk (HR, 27.2).

• August 6, 2026JAMA OncologyPRO B Trial (DRKS00024015)

  Weekly Digital Symptom Monitoring Cuts Fatigue in Metastatic Breast Cancer

  The multicenter PRO B trial randomized 924 patients with metastatic breast cancer across 52 German centers to weekly alert-based electronic patient-reported outcome (ePRO) monitoring or usual quarterly PRO monitoring, with fatigue at 6 months as the primary endpoint.

• July 30, 2026JAMA OncologyI-SPY2 (NCT01042379)

  Dual PD-1/LAG-3 Blockade Nearly Doubles Complete Response in High-Risk Breast Cancer

  A Phase 2 arm of the adaptive I-SPY2 platform trial (78 patients treated 2020-2021, compared against 350 historical controls) tested adding cemiplimab (anti-PD-1) and fianlimab (anti-LAG-3) to neoadjuvant chemotherapy in high-risk, stage II-III, ERBB2 (HER2)-negative breast cancer.

• July 16, 2026JAMA OncologySystematic review and trial-level meta-analysis of 21 randomized trials (no single ClinicalTrials.gov registration)

  Investigator-Assessed PFS Matches BICR in HR+/HER2-Negative Metastatic Breast Cancer

  A systematic review and trial-level meta-analysis of 21 randomized trials (9,165 pooled patients) in HR+/HER2-negative metastatic breast cancer compares investigator (local site)-assessed progression-free survival against blinded independent central review (BICR), asking whether the added cost and complexity of BICR is actually needed.

• March 9, 2026Journal of Clinical OncologyVIKTORIA-1 (NCT05501886)

  VIKTORIA-1 Trial: Gedatolisib Demonstrates Superior Efficacy in PIK3CA Wild-Type HR+/HER2- Metastatic Breast Cancer

  VIKTORIA-1 is a Phase 3, open-label, randomized, global trial enrolling 392 PIK3CA wild-type patients with HR+/HER2- metastatic or locally advanced breast cancer who had progressed on prior CDK4/6 inhibitor plus nonsteroidal aromatase inhibitor therapy